Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Blood (2022) 140 (Supplement 1): 1479–1480.

https://doi.org/10.1182/blood-2022-158981

Published: 2022

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK , DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis

Blood (2017) 130 (Supplement 1): 822.

https://doi.org/10.1182/blood.V130.Suppl_1.822.822

Published: 2017

Journal Articles

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Jan Sundberg, Lone Bredo Pedersen, Elisabeth Ralfkiær, Marja-Liisa Karjalainen-Lindsberg, Christer Sundström, Mats Ehinger, Christian Geisler, Mats Jerkeman

Blood (2016) 128 (14): 1814–1820.

https://doi.org/10.1182/blood-2016-03-704023

Published: 2016

Includes: Supplemental data

Journal Articles

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

Blood (2016) 127 (24): 3026–3034.

https://doi.org/10.1182/blood-2015-12-686550

Published: 2016

Includes: Supplemental data

Journal Articles

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Fabrice Jardin, MD PhD, Anais Pujals, PhD, Laura Pelletier, PhD, Elodie Bohers, PhD, Vincent Camus, Sylvain Mareschal, Sydney Dubois, Marlène Ochman, MD, Francois Lemonnier, MD, Pierre-Julien Viailly, Philippe Bertrand, PhD, Catherine Maingonnat, Alexandra Traverse-Glehen, Philippe Gaulard, MD PhD, Diane Damotte, MD PhD, Richard Delarue, MD, Corinne Haioun, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD, Christian Argueta, PhD, Gilles Andre Salles, MD PhD, Jean-Philippe Jais, MD PhD, Martin Figeac, PhD, Christiane Copie-Bergman, MD PhD, Thierry Molina, Jean-Michel Picquenot, PhD, Marie Cornic, Thierry Fest, MD PhD, Noel Milpied, Emilie Lemasle, MD, Aspasia Stamatoullas, MD, Peter Moeller, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Christer Sundstrom, MD PhD, Christian Bastard, MD PhD, Hervé Tilly, MD PhD, Karen Leroy, MD PhD

Blood (2015) 126 (23): 129.

https://doi.org/10.1182/blood.V126.23.129.129

Published: 2015

Journal Articles

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Blood (2015) 125 (17): 2669–2677.

https://doi.org/10.1182/blood-2014-06-584193

Published: 2015

Includes: Supplemental data

Journal Articles

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

Simon Husby, MD, Lone Bredo Pedersen, Ulrik Ralfkiær, PhD-student, Christian Garde, Sara Ek, Arne Kolstad, MD PhD, Mats Jerkeman, MD PhD, Anna Laurell, Riikka Räty, Anja Pedersen, Christer Sundström, Marja-Liisa Karjalainen-Lindsberg, Jan Delabie, MD PhD, Erik Clasen-Linde, MD, Christopher Workman, PhD, Christian H Geisler, Kirsten Grønbæk, MD DMSc

Blood (2014) 124 (21): 2994.

https://doi.org/10.1182/blood.V124.21.2994.2994

Published: 2014

Journal Articles

How Many Ontogenetic Roads to Mantle-Cell Lymphoma? Immunogenetic and Immunohistochemical Evidence

Blood (2014) 124 (21): 3005.

https://doi.org/10.1182/blood.V124.21.3005.3005

Published: 2014

Journal Articles

Nordic MCL3 study: 90 Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Blood (2014) 123 (19): 2953–2959.

https://doi.org/10.1182/blood-2013-12-541953

Published: 2014

Journal Articles

Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort

Lena Nordström, Venera Kuci, Sandra Sernbo, Kirsten Groenbaek, MD, DMSc, Arne Kolstad, Riika Räty, Marja-Liisa Karjalainen, Christian Geisler, Elisabeth Ralfkiaer, MD, DMSc, Christer Sundström, Anna Laurell, Jan Delabie, Mats Ehinger, Mats Jerkeman, Sara Ek

Blood (2013) 122 (21): 4272.

https://doi.org/10.1182/blood.V122.21.4272.4272

Published: 2013

Journal Articles

High Expression of Activation-Induced Cytidine Deaminase and in Vivo Class Switch Recombination in Mantle Cell Lymphoma: Further Support for Antigen Involvement in Lymphomagenesis

Blood (2012) 120 (21): 1538.

https://doi.org/10.1182/blood.V120.21.1538.1538

Published: 2012

Journal Articles

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Blood (2012) 120 (21): 747.

https://doi.org/10.1182/blood.V120.21.747.747

Published: 2012

Journal Articles

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

Eva Kimby, M.D., Ph.D., Björn Östenstad, Peter de Nully Brown, Harald Holte, Jr., MD, PhD, Hans Hagberg, Martin Erlanson, Ola Linden, MD, Marie Nordström, MD, PhD, Christer Sundstrom, MD, PhD

Blood (2012) 120 (21): 794.

https://doi.org/10.1182/blood.V120.21.794.794

Published: 2012

Journal Articles

MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

Wendy Cuccuini, Josette Briere, Nicolas Mounier, Hans-Ullrich Voelker, Andreas Rosenwald, Christer Sundstrom, Sergio Cogliatti, Edouard Hirchaud, Loic Ysebaert, Dominique Bron, Jean Soulier, Philippe Gaulard, Remi Houlgatte, Christian Gisselbrecht, Catherine Thieblemont

Blood (2012) 119 (20): 4619–4624.

https://doi.org/10.1182/blood-2012-01-406033

Published: 2012

Journal Articles

MYC + Diffuse Large B Cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage Therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem Cell Transplantation (ASCT). A BioCORAL Report

Wendy Cuccuini, Josette Briere, Nicolas Mounier, MD, PhD, Hans-Ullrich Voelker, Andreas Rosenwald, MD, Christer Sundstrom, MD, PhD, Sergio Cogliatti, Dominique Bron, MD, Edouard Hirchaud, Jean Soulier, MD, Philippe Gaulard, MD, Remi Houlgatte, C. Gisselbrecht, MD, Catherine Thieblemont, MD

Blood (2011) 118 (21): 594.

https://doi.org/10.1182/blood.V118.21.594.594

Published: 2011

Journal Articles

R-CHOEP-14 × 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2–3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18–65 Years.

Harald Holte, MD, PhD, Sirpa LeppÃ¤, MD, PhD, Magnus Bjorkholm, MD, PhD, Øystein Fluge, MD, PhD, Sirkku Jyrkkiö, MD, PhD, Jan Delabie, MD, PhD, Christer Sundstrom, MD, PhD, Marja-Liisa Karjalainen-Lindsberg, Martin Erlanson, MD, PhD, Arne Kolstad, MD, PhD, Alexander Fosså, MD, PhD, Bj∅rn Østenstad, MD, PhD, Eva Löfvenberg, MD, Marie Nordström, MD, PhD, Lars Möller Pedersen, MD, PhD, Harald Anderson, PhD, Mats Jerkeman, MD, PhD, Mikael Eriksson, MD, PhD

Blood (2010) 116 (21): 2805.

https://doi.org/10.1182/blood.V116.21.2805.2805

Published: 2010

Journal Articles

Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study

Catherine Thieblemont, MD, Josette Briere, MD, Nicolas Mounier, Hans-Ullrich Voelker, Wendy Cuccini, Edouard Hirchaud, Andreas Rosenwald, Andrew Jack, PhD, MB, Christer Sundstrom, MD, PhD, Sergio Cogliatti, Phlippe Trougouboff, Ludmila Boudova, Jean Soulier, Remi Houlgatte, Norbert Schmitz, MD, Philippe Gaulard, Christian Gisselbrecht, MD

Blood (2010) 116 (21): 993.

https://doi.org/10.1182/blood.V116.21.993.993

Published: 2010

Journal Articles

Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Blood (2010) 116 (21): 3565.

https://doi.org/10.1182/blood.V116.21.3565.3565

Published: 2010

Journal Articles

Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Blood (2010) 116 (21): 3566.

https://doi.org/10.1182/blood.V116.21.3566.3566

Published: 2010

NARROW

Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK , DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

How Many Ontogenetic Roads to Mantle-Cell Lymphoma? Immunogenetic and Immunohistochemical Evidence

Nordic MCL3 study: 90 Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort

High Expression of Activation-Induced Cytidine Deaminase and in Vivo Class Switch Recombination in Mantle Cell Lymphoma: Further Support for Antigen Involvement in Lymphomagenesis

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

MYC + Diffuse Large B Cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage Therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem Cell Transplantation (ASCT). A BioCORAL Report

R-CHOEP-14 × 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2–3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18–65 Years.

Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study

Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only